Literature DB >> 26975364

Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients.

Julia E Neumann1, Mario M Dorostkar1, Andrey Korshunov1, Christian Mawrin1, Arend Koch1, Armin Giese1, Ulrich Schüller2.   

Abstract

Glioblastomas (GBMs) are malignant brain tumors that can be divided into different molecular subtypes based on genetics, global gene expression, and methylation patterns. Among these subgroups, "IDH" GBMs carry mutations within IDH1 or IDH2 The "K27" and "G34" subgroups are characterized by distinct mutations within Histone 3 (H3). These subtypes can be identified by sequencing methods and are particularly found in younger patients. To determine whether the molecular subtypes correlate with distinct histological features among the diverse histologic patterns of GBM, we performed a blinded assessment of the histology of GBMs of 77 patients ≤30 years old at the time of biopsy. The tumors were of the following molecular subtypes: IDH (n = 12), H3 K27M (n = 25), H3 G34R (n = 12), or no IDH/H3 mutations (n = 28). Of IDH-mutated cases, 75% had microcystic features or gemistocytic tumor cells. K27 GBMs had higher cell densities and pronounced nuclear pleomorphism, with 28% harboring tumor giant cells. All G34 GBMs had variable extents of a poorly differentiated/primitive neuroectodermal tumor-like morphology. GBMs without IDH/H3 mutations had foci of epitheliod-appearing cells. Thus, molecular GBM subgroups are associated with distinct histological patterns, suggesting that morphological features reflect the specific underlying molecular genetic abnormalities.
© 2016 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  G34R; Glioblastoma; H3; Histology; IDH1; K27M; Molecular subgroups.

Mesh:

Substances:

Year:  2016        PMID: 26975364     DOI: 10.1093/jnen/nlw015

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

1.  Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.

Authors:  Ekkehard Hewer; Nadine Prebil; Sabina Berezowska; Marielena Gutt-Will; Philippe Schucht; Matthias S Dettmer; Erik Vassella
Journal:  Virchows Arch       Date:  2017-08-19       Impact factor: 4.064

2.  Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.

Authors:  Süheyla Uyar Bozkurt; A Dagcinar; B Tanrikulu; N Comunoglu; B C Meydan; M Ozek; B Oz
Journal:  Childs Nerv Syst       Date:  2017-10-24       Impact factor: 1.475

3.  Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults.

Authors:  Stefanie Thust; Caroline Micallef; Sachi Okuchi; Sebastian Brandner; Atul Kumar; Kshitij Mankad; Stephen Wastling; Laura Mancini; Hans Rolf Jäger; Ananth Shankar
Journal:  Quant Imaging Med Surg       Date:  2021-01

4.  Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.

Authors:  Xin Cui; Chao Ma; Varshini Vasudevaraja; Jonathan Serrano; Jie Tong; Yansong Peng; Michael Delorenzo; Guomiao Shen; Joshua Frenster; Renee-Tyler Tan Morales; Weiyi Qian; Aristotelis Tsirigos; Andrew S Chi; Rajan Jain; Sylvia C Kurz; Erik P Sulman; Dimitris G Placantonakis; Matija Snuderl; Weiqiang Chen
Journal:  Elife       Date:  2020-09-10       Impact factor: 8.140

5.  Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults.

Authors:  Jianling Ji; Kristiyana Kaneva; Matthew C Hiemenz; Girish Dhall; Tom Belle Davidson; Anat Erdreich-Epstein; Debra Hawes; Kyle Hurth; Ashley S Margol; Anna J Mathew; Nathan J Robison; Ryan J Schmidt; Hung N Tran; Alexander R Judkins; Jennifer A Cotter; Jaclyn A Biegel
Journal:  Neurooncol Adv       Date:  2021-02-25

6.  Pediatric Giant Cell Glioblastoma Presenting with Intracranial Dissemination at Diagnosis: A Case Report.

Authors:  Takamasa Kinoshita; Hirohito Yano; Noriyuki Nakayama; Natsuko Suzui; Tomohiro Iida; Saori Endo; Shiho Yasue; Michio Ozeki; Kazuhiro Kobayashi; Tatsuhiko Miyazaki; Toru Iwama
Journal:  NMC Case Rep J       Date:  2021-06-05

7.  Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?

Authors:  Nico Teske; Philipp Karschnia; Jonathan Weller; Sebastian Siller; Mario M Dorostkar; Jochen Herms; Louisa von Baumgarten; Joerg Christian Tonn; Niklas Thon
Journal:  J Neurooncol       Date:  2021-12-13       Impact factor: 4.130

8.  Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.

Authors:  Thiébaud Picart; Marc Barritault; Delphine Poncet; Lise-Prune Berner; Cristina Izquierdo; Emeline Tabouret; Dominique Figarella-Branger; Ahmed Idbaïh; Franck Bielle; Véronique Bourg; Fanny Burel Vandenbos; Elizabeth Cohen-Jonathan Moyal; Emmanelle Uro-Coste; Jacques Guyotat; Jérôme Honnorat; Mathieu Gabut; David Meyronet; François Ducray
Journal:  Neurooncol Adv       Date:  2021-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.